Seok Joo Lee – CEO, ISU Abxis, South Korea
ISU Abxis, a subsidiary of the ISU conglomerate, is a biotech company with a focus on orphan drugs and rare disease. CEO Seok Joo Lee explains the rationale behind his…
Address: 18th Floor, Hanjin Main Bld, 118, Namdaemunno-2-ga, Seoul,Republic of Korea
Tel: +82 2 772 4000
With more than thirty years of experience as one of Republic of Korea’s premiere full-service law firms, Lee & Ko has a widely recognized and long-established record of excellence in providing expert legal advice and representation to its diverse clientele in domestic and international matters involving all areas of legal practice. ith a wealth of experience in virtually all aspects of corporate law practice, Lee & Ko continues to be a highly regarded leader among Republic of Korean law firms in providing excellent legal services and creative approaches to both domestic and foreign clients doing business in or with Republic of Korea. With some of Republic of Korea’s most experienced and capable corporate law practitioners among its partners and associates, Lee & Ko’s clients receive the highest quality, the most efficient, and the most innovative legal assistance available. Lee & Ko has a distinguished and well-deserved reputation for consistently providing timely, up-to-date, accurate and reliable legal assistance with all manner of corporate legal matters, including incorporation and registration, corporate governance issues and the issuance of corporate securities.
In addition, Lee & Ko has one of Republic of Korea’s most capable, versatile and extensive legal practices in domestic and cross-border mergers and acquisitions. Lee & Ko has served as key legal counsel for innumerable foreign and domestic clients in connection with a broad range of highly complex and sensitive transactions, particularly in recent decades as the Republic of Korean corporate landscape has become more international and complex.
ISU Abxis, a subsidiary of the ISU conglomerate, is a biotech company with a focus on orphan drugs and rare disease. CEO Seok Joo Lee explains the rationale behind his…
Looking at what it takes to be a country manager of a multinational pharma company in some of the world’s most challenging markets. DHR International’s Helen Park outlines what she…
Syneos Health, established through a merger in 2017, has held a foothold in Korea through its legacy organisations for over 10 years. Sora Lee, general manager of Syneos Korea, provides…
SK Group, the second largest conglomerate in South Korea and renowned as a leader in energy, telecommunications, and the semiconductor business, entered drug development in 1993. In an exclusive interview,…
Bong Gil Nam, chairman and owner of Pharmbio Korea, offers his insights on his company’s importance in differentiating itself from the generic competitors in the market. Mr Nam also explains…
Bioneer, founded in 1992, lays claim to be Korea’s oldest biotechnology company. President, founder and CEO, Dr Han-Oh Park introduces the technological advances they have developed in molecular research tools,…
The Korea Drug Development Fund (KDDF) is a government-funded organization created to accelerate innovation activities in the Korean life sciences sector. In this interview, Samuel Muk explains how he integrated…
Dr Nam Han Cho, president of the International Diabetes Federation (IDF) and professor of Preventive Medicine at the Ajou University School of Medicine in South Korea is taking stock of his…
This week, the Korean Ministry of Food and Drug Safety announced that it would enhance drug safety management and make a new, streamlined review process for advanced healthcare goods. The…
The administration of President Moon Jae-in is moving to ensure the enduring success of South Korea’s healthcare and life sciences industries through increased international collaboration. However, some pharma insiders are…
Narihiko Yoshii, president of Mitsubishi Tanabe Pharma Korea unveils the value that they are bringing to Korean patients by utilising legislation regarding orphan drugs to fast track the market entry…
It was less than a decade ago (2011) that Samsung Biologics was a new kid on the block amongst Korea’s booming biotech conglomerates. Since then the company has snowballed, building…
See our Cookie Privacy Policy Here
